DermTech Inc (DMTK) USD0.0001
DermTech, Inc. is a molecular dermatology company that focuses on skin cancer. The Company develops products that facilitate the early detection of skin cancers, assess inflammatory diseases and customize drug treatments. The Company provides Adhesive Skin Collection Kit, which is designed to collect stratum corneum tissues of the skin from all locations of the body, with the exception of mucosals surfaces, palmar and plantar surfaces, and areas with excessive non-vellus hair. It provides Pigmented Lesion Assay (PLA), which assesses pigmented skin lesions, moles or dark skin spots for melanoma. It offers Nevome, which is the test to non-invasively identify pigmented lesions by analyzing known deoxyribonucleic acid (DNA) mutation risk factors for melanoma. The Company is also engaged in developing gene expression assays to identify cytokine inflammatory profiles that assist clinicians in guiding therapy. It also offers ResponseTNF product and CytokineEx 17 product.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.